Edwards Lifesciences/$EW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Ticker
$EW
Sector
Primary listing
NYSE
Employees
16,000
Headquarters
Website
EW Metrics
BasicAdvanced
$47B
44.54
$1.83
0.94
-
Price and volume
Market cap
$47B
Beta
0.94
52-week high
$87.89
52-week low
$65.94
Average daily volume
4.9M
Financial strength
Current ratio
3.716
Quick ratio
2.833
Long term debt to equity
6.587
Total debt to equity
6.862
Interest coverage (TTM)
80.29%
Profitability
EBITDA (TTM)
1,788.067
Gross margin (TTM)
78.01%
Net profit margin (TTM)
17.69%
Operating margin (TTM)
26.99%
Effective tax rate (TTM)
17.04%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
7.65%
Return on equity (TTM)
10.35%
Valuation
Price to earnings (TTM)
44.542
Price to revenue (TTM)
7.869
Price to book
4.65
Price to tangible book (TTM)
6.37
Price to free cash flow (TTM)
35.763
Free cash flow yield (TTM)
2.80%
Free cash flow per share (TTM)
2.283
Growth
Revenue change (TTM)
11.55%
Earnings per share change (TTM)
-73.70%
3-year revenue growth (CAGR)
10.77%
10-year revenue growth (CAGR)
9.30%
3-year earnings per share growth (CAGR)
-9.06%
10-year earnings per share growth (CAGR)
9.35%
What the Analysts think about EW
Analyst ratings (Buy, Hold, Sell) for Edwards Lifesciences stock.
EW Financial Performance
Revenues and expenses
EW Earnings Performance
Company profitability
EW News
AllArticlesVideos
Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose
Business Wire·2 weeks ago
Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences
Business Wire·3 weeks ago
Edwards Lifesciences scraps anti-copycat policy, EU drops antitrust investigation
Reuters·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Edwards Lifesciences stock?
Edwards Lifesciences (EW) has a market cap of $47B as of March 10, 2026.
What is the P/E ratio for Edwards Lifesciences stock?
The price to earnings (P/E) ratio for Edwards Lifesciences (EW) stock is 44.54 as of March 10, 2026.
Does Edwards Lifesciences stock pay dividends?
No, Edwards Lifesciences (EW) stock does not pay dividends to its shareholders as of March 10, 2026.
When is the next Edwards Lifesciences dividend payment date?
Edwards Lifesciences (EW) stock does not pay dividends to its shareholders.
What is the beta indicator for Edwards Lifesciences?
Edwards Lifesciences (EW) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.